Laxoberon (Sodium Picosulfate Monohydrate)

After oral intake, sodium picosulfate reaches the colon where intestinal bacteria convert it into an active metabolite. This metabolite activates enteric nerve endings, increasing peristaltic contractions and fluid secretion into the lumen, which together accelerate transit and result in a bowel movement.

The dose of Laxoberon is individualized by the prescribing clinician based on the indication, patient age, and clinical situation. Healthcare professionals may prescribe a single or split dose regimen, but the exact amount and timing should follow the prescriber’s instructions.

Safety data for sodium picosulfate in pregnancy and lactation are limited. The product should only be used when the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Laxoberon, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Laxoberon (sodium picosulfate) is a stimulant laxative that works by activating colonic nerves, whereas polyethylene glycol (PEG) solutions act as osmotic agents that retain water in the lumen. Sodium picosulfate typically requires a smaller volume of liquid and a shorter preparation time, but PEG may be preferred for patients needing a gentler, isotonic cleanse.

Store Laxoberon at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight to maintain stability. Keep out of reach of children and do not use if the packaging is damaged.

Laxoberon is taken orally, usually dissolved in a specified amount of water as directed by the prescriber. It should be consumed on an empty stomach or as instructed, and the patient should follow any additional fluid intake recommendations to reduce the risk of dehydration.

The most serious adverse events associated with Laxoberon include severe dehydration, significant electrolyte disturbances such as hyponatremia or hypokalemia, and, rarely, colonic perforation. Patients should seek immediate medical attention if they experience persistent vomiting, dizziness, fainting, bloody stools, or severe abdominal pain.

Laxoberon should be avoided in individuals with known or suspected intestinal obstruction, perforated bowel, acute abdomen, severe inflammatory bowel disease, or hypersensitivity to sodium picosulfate. It is also contraindicated in patients for whom rapid fluid loss could be hazardous, unless closely monitored by a physician.